S Adams1, S Loi2, D Toppmeyer3, D W Cescon4, M De Laurentiis5, R Nanda6, E P Winer7, H Mukai8, K Tamura9, A Armstrong10, M C Liu11, H Iwata12, L Ryvo13, P Wimberger14, H S Rugo15, A R Tan16, L Jia17, Y Ding17, V Karantza17, P Schmid18. 1. Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, USA. Electronic address: sylvia.adams@nyumc.org. 2. Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia. 3. Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA. 4. Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada. 5. Dipartimento di Senologia, Istituto Nazionale Tumori - "Fondazione Pascale," Naples, Italy. 6. Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago. 7. Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. 8. Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa. 9. Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. 10. Breast Disease Research Group, The Christie NHS Foundation Trust, Manchester, UK. 11. Department of Oncology, Mayo Clinic, Rochester, USA. 12. Aichi Cancer Center Hospital, Nagoya, Japan. 13. Division of Oncology, Sourasky Medical Center (Ichilov), Tel Aviv, Israel. 14. Department of Gynecology and Obstetric, University Carl Gustav Carus, TU Dresden, Dresden, Germany. 15. Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco. 16. Levine Cancer Institute, Atrium Health, Charlotte. 17. Merck & Co., Inc., Kenilworth, USA. 18. Centre for Experimental Cancer Medicin, Barts Cancer Institute, Queen Mary University London, London, UK.
Abstract
BACKGROUND: Standard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. However, outcomes are poor, and new treatment options are needed. In cohort B of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as first-line therapy for patients with PD-L1-positive mTNBC. PATIENTS AND METHODS: Eligible patients had centrally confirmed mTNBC, no prior systemic anticancer therapy for metastatic disease, measurable disease at baseline per RECIST v1.1 by central review, no radiographic evidence of central nervous system metastases, and a tumor PD-L1 combined positive score ≥1. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. The primary end point was safety. Secondary end points included objective response rate, disease control rate (percentage of patients with complete or partial response or stable disease for ≥24 weeks), duration of response, progression-free survival and overall survival. RESULTS: All 84 patients enrolled were women, and 73 (86.9%) received prior (neo)adjuvant therapy. Fifty-three (63.1%) patients had treatment-related adverse events (AEs), including 8 patients (9.5%) with grade 3 severity; no patients experienced grade 4 AEs or died because of treatment-related AEs. Four patients had a complete response and 14 had a partial response, for an objective response rate of 21.4% (95% CI 13.9-31.4). Of the 13 patients with stable disease, 2 had stable disease lasting ≥24 weeks, for a disease control rate of 23.8% (95% CI 15.9-34.0). At data cut-off, 8 of 18 (44.4%) responses were ongoing, and median duration of response was 10.4 months (range 4.2 to 19.2+). Median progression-free survival was 2.1 months (95% CI 2.0-2.2), and median overall survival was 18.0 months (95% CI 12.9-23.0). CONCLUSIONS: Pembrolizumab monotherapy had a manageable safety profile and showed durable antitumor activity as first-line therapy for patients with PD-L1-positive mTNBC. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02447003.
BACKGROUND: Standard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. However, outcomes are poor, and new treatment options are needed. In cohort B of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as first-line therapy for patients with PD-L1-positive mTNBC. PATIENTS AND METHODS: Eligible patients had centrally confirmed mTNBC, no prior systemic anticancer therapy for metastatic disease, measurable disease at baseline per RECIST v1.1 by central review, no radiographic evidence of central nervous system metastases, and a tumorPD-L1 combined positive score ≥1. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. The primary end point was safety. Secondary end points included objective response rate, disease control rate (percentage of patients with complete or partial response or stable disease for ≥24 weeks), duration of response, progression-free survival and overall survival. RESULTS: All 84 patients enrolled were women, and 73 (86.9%) received prior (neo)adjuvant therapy. Fifty-three (63.1%) patients had treatment-related adverse events (AEs), including 8 patients (9.5%) with grade 3 severity; no patients experienced grade 4 AEs or died because of treatment-related AEs. Four patients had a complete response and 14 had a partial response, for an objective response rate of 21.4% (95% CI 13.9-31.4). Of the 13 patients with stable disease, 2 had stable disease lasting ≥24 weeks, for a disease control rate of 23.8% (95% CI 15.9-34.0). At data cut-off, 8 of 18 (44.4%) responses were ongoing, and median duration of response was 10.4 months (range 4.2 to 19.2+). Median progression-free survival was 2.1 months (95% CI 2.0-2.2), and median overall survival was 18.0 months (95% CI 12.9-23.0). CONCLUSIONS:Pembrolizumab monotherapy had a manageable safety profile and showed durable antitumor activity as first-line therapy for patients with PD-L1-positive mTNBC. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02447003.
Authors: Sara M Tolaney; Romualdo Barroso-Sousa; Tanya Keenan; Tianyu Li; Lorenzo Trippa; Ines Vaz-Luis; Gerburg Wulf; Laura Spring; Natalie Faye Sinclair; Chelsea Andrews; Jessica Pittenger; Edward T Richardson; Deborah Dillon; Nancy U Lin; Beth Overmoyer; Ann H Partridge; Eliezer Van Allen; Elizabeth A Mittendorf; Eric P Winer; Ian E Krop Journal: JAMA Oncol Date: 2020-10-01 Impact factor: 31.777
Authors: Bruna Cerbelli; Andrea Botticelli; Annalinda Pisano; Angelina Pernazza; Domenico Campagna; Alessandro De Luca; Paolo Antonio Ascierto; Maria Gemma Pignataro; Maria Pelullo; Carlo Della Rocca; Paolo Marchetti; Lucio Fortunato; Leopoldo Costarelli; Giulia d'Amati Journal: Virchows Arch Date: 2019-12-18 Impact factor: 4.064
Authors: Rita Nanda; Minetta C Liu; Christina Yau; Rebecca Shatsky; Lajos Pusztai; Anne Wallace; A Jo Chien; Andres Forero-Torres; Erin Ellis; Heather Han; Amy Clark; Kathy Albain; Judy C Boughey; Nora T Jaskowiak; Anthony Elias; Claudine Isaacs; Kathleen Kemmer; Teresa Helsten; Melanie Majure; Erica Stringer-Reasor; Catherine Parker; Marie C Lee; Tufia Haddad; Ronald N Cohen; Smita Asare; Amy Wilson; Gillian L Hirst; Ruby Singhrao; Katherine Steeg; Adam Asare; Jeffrey B Matthews; Scott Berry; Ashish Sanil; Richard Schwab; W Fraser Symmans; Laura van 't Veer; Douglas Yee; Angela DeMichele; Nola M Hylton; Michelle Melisko; Jane Perlmutter; Hope S Rugo; Donald A Berry; Laura J Esserman Journal: JAMA Oncol Date: 2020-05-01 Impact factor: 31.777
Authors: Eric T Alexander; Kelsey Mariner; Julia Donnelly; Otto Phanstiel; Susan K Gilmour Journal: Mol Cancer Ther Date: 2020-08-03 Impact factor: 6.261
Authors: Sulaiman S Alhudaithi; Rashed M Almuqbil; Hanming Zhang; Elizabeth R Bielski; Wei Du; Fatemah S Sunbul; Paula D Bos; Sandro R P da Rocha Journal: Mol Pharm Date: 2020-11-10 Impact factor: 4.939
Authors: Ann Byrne; Peter Savas; Sneha Sant; Ran Li; Balaji Virassamy; Stephen J Luen; Paul A Beavis; Laura K Mackay; Paul J Neeson; Sherene Loi Journal: Nat Rev Clin Oncol Date: 2020-02-28 Impact factor: 66.675